• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Crit Care . Longitudinal mycological profiling of influenza-associated and COVID-19-associated pulmonary aspergillosis

tetano

Editor, Senior Moderator
Crit Care


. 2026 Jan 9.
doi: 10.1186/s13054-025-05830-9. Online ahead of print. Longitudinal mycological profiling of influenza-associated and COVID-19-associated pulmonary aspergillosis

Valentine Delanote[SUP] 1 2 [/SUP], Jannes Heylen[SUP] 1 3 [/SUP], Hanne Moon Lauwers[SUP] 1 [/SUP], Cato Jacobs[SUP] 1 [/SUP], Lenn Maessen[SUP] 1 [/SUP], Yves Debaveye[SUP] 4 5 [/SUP], Pascal Frederiks[SUP] 6 7 [/SUP], Greet Hermans[SUP] 1 5 [/SUP], Johan Maertens[SUP] 2 3 [/SUP], Philippe Meersseman[SUP] 1 3 [/SUP], Marijke Peetermans[SUP] 1 3 [/SUP], Lore Vanderbeke[SUP] 8 [/SUP], Eric Van Wijngaerden[SUP] 3 8 [/SUP], Alexander Wilmer[SUP] 1 3 [/SUP], Katrien Lagrou[SUP] 3 9 [/SUP], Joost Wauters[SUP] #[/SUP][SUP] 1 3 [/SUP], Simon Feys[SUP] #[/SUP][SUP] 10 11 [/SUP]



Affiliations
Free article Abstract

Objectives: Influenza- and COVID-19-associated pulmonary aspergillosis (IAPA and CAPA respectively) are associated with increased mortality in critically ill patients. We evaluated whether longitudinal bronchoalveolar lavage (BAL) galactomannan (GM) dynamics predict clinical outcomes in these patients.
Methods: In a retrospective cohort (2009-2024) at a tertiary care ICU in Belgium, 180 adult patients with probable/proven IAPA (n = 68) or CAPA (n = 112) requiring mechanical ventilation were included. A total of 698 BAL samples were analysed. GM optical density values were modelled using linear mixed-effects models (10- and 30-day follow-up windows), with outcome measures at 30 and 90 days. Bayesian joint models linked longitudinal GM trends with time-to-death, adjusting for age, Charlson Comorbidity Index (CCI) and immunosuppression. Associations between Aspergillus culture results dynamics and mortality were also assessed.
Results: In general, BAL GM values declined significantly over days after diagnosis of aspergillosis, with steeper reductions in survivors (interaction p < 0.05). Joint models revealed each unit increase in GM over time corresponded to a 19% higher hazard of death at both 30 (aHR 1.19, p = 0.02) and 90 days (aHR 1.19, p = 0.007) after ICU admission. Persistent BAL culture positivity also correlated with worse outcomes.
Conclusions: In this large virus-associated pulmonary aspergillosis cohort, BAL GM kinetics emerged as a potential prognostic biomarker. Early and sustained increases in BAL GM values identify patients at increased risk of mortality.


 
Back
Top